Paper Details

  1. Home
  2. Paper Details

Nadolol eye drops in glaucoma and ocular hypertension: a controlled clinical study of dose response and duration of action.

Author: KrieglsteinG K

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Nadolol eye drops effectively reduced intraocular pressure in a dose-dependent manner, with a duration of action exceeding 6 hours for 0.3% and 9 hours for 1.5% and 2% concentrations. No significant effects on blood pressure, heart rate, or ocular irritation were observed.
Paper Details　
Original Abstract of the Article :
The betablocker nadolol was investigated with respect to dose-response relationship and duration of action on the basis of single-drop application in four groups of ten volunteers each. A significant dose-dependent IOP reduction could be verified between 0.3% and 2% drug concentration with increasin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/BF00429291

データ提供：米国国立医学図書館（NLM）

The Effectiveness of Nadolol Eye Drops in Treating Glaucoma and Ocular Hypertension

My fellow researchers, we're delving into the fascinating realm of ophthalmology, specifically focusing on the treatment of glaucoma and ocular hypertension. This study explores the efficacy of nadolol eye drops in reducing intraocular pressure (IOP), a key factor in these conditions. Employing a controlled clinical trial, researchers investigated the dose-response relationship and duration of action of nadolol in four groups of volunteers. The findings reveal a significant dose-dependent IOP reduction with increasing duration of action. Notably, the maximum IOP effect was observed 3 hours after drug application, with varying degrees of effectiveness depending on the concentration of nadolol. This research presents compelling evidence for the potential of nadolol eye drops as a treatment option for glaucoma and ocular hypertension, highlighting its ability to effectively manage IOP without affecting blood pressure or heart rate.

Nadolol: A Promising Treatment for Glaucoma and Ocular Hypertension

The results of this study suggest that nadolol eye drops could be a viable treatment option for individuals suffering from glaucoma and ocular hypertension. The dose-dependent reduction in IOP, coupled with the extended duration of action, demonstrates the drug's potential to effectively manage these conditions. The lack of adverse effects on blood pressure and heart rate adds to its appeal as a safe and well-tolerated treatment.

Keeping Your Eyes Healthy

Glaucoma and ocular hypertension can be managed with proper treatment. Consult an ophthalmologist if you experience vision changes or are diagnosed with these conditions. While this study offers promising evidence for nadolol eye drops, it's essential to discuss your treatment options with your doctor and adhere to their guidance.

Dr.Camel's Conclusion

This research, like a refreshing oasis in the vast desert of ophthalmic studies, provides valuable insights into the potential of nadolol eye drops for managing glaucoma and ocular hypertension. The effectiveness and safety of nadolol present a glimmer of hope for patients seeking relief from these conditions.

Date :
  1. Date Completed 1982-03-13
  2. Date Revised 2019-09-13
Further Info :

Pubmed ID

6119925

DOI: Digital Object Identifier

10.1007/BF00429291

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.